"You sound as jazzed talking about BETonMACE while answering  Cabel's questions as some of the RVX management did while talking to shareholders at the AGM a couple of weeks ago."

Yes, jazzed, pumped, ecstatic, jacked.....somewhere in that mix.

EASD presentation for Resverlogix tomorrow. AHA still over 5 weeks away, but I'm really looking forward to seeing the baseline patient characteristics for the full BETonMACE population presented at AHA on Nov 11th.

"Cardiovascular Evaluation of the Selective BET Inhibitor, Apabetalone, in ACS Patients With Diabetes: Baseline Characteristics of the BETonMACE CV Outcomes Study." 

We've seen select (see AAIC and ERA-EDTA posters here) baseline stats for the smaller BETonMACE cognition and CKD sub-groups, but this AHA presentation will be the whole ~2400 patient set. Pay attention to the HDL-C/apoAI, fasting glucose/HbA1c, hsCRP, LDL-C, alkaline phosphatase and neutrophile to lymphocyte ratio (NLR) to get confirmation that this BETonMACE population is indeed high-risk and that apabetalone has huge potential for high-reward (for both patients and shareholders!).

BearDownAZ